




What we will talk about ✤ Artifacts ✤Abscess v GBM ✤ Use of smears ✤Tumor v Demyelinating How to look at smears and FS Recurrence v **Treatment effect** ✤ Sampling issues: "Next to" Meningioma and SFT Immunochemistry for neuropathology





<section-header><section-header><section-header>




Astrocytic processes


• Identification of the presence or absence of glial/ astrocytic processes is one of most important observations in smear/crush preparations.

- Astrocytic (+) v nonastrocytic (-) tumors
- Gliosis (seen here)

• Typical brain granulofibrillary pale background with mixed cell populations (gray matter) or oligodendrocytepredominant (white matter)

 Predominant (white matter)
 Scattered cells with larger ovoid nuclei and numerous obvious processes extending from eosinophilic cell body









• Predominant population of monotonous round-to-oval nuclei without processes


• Background is typical granulo-fibrillary matrix of white matter


These are NOT glial processes:

pale not strongly eosinophilic
Wispy or granulofibrillary, not dense/solid










Oligodendroglioma

• Smear: Round cells without processes.

 Cells are larger than background oligodendrocytes and with more open nuclei

• Frozen section: Diffuse moderately hypercellular proliferation/infiltrate in a background of preserved parenchyma

> Predominant population matches the smear




Processes or Stretched cell body?


Non-glial tumors with a fibrous stroma will occasional smear well, particularly when the tumor is highly cellular (less stroma).


In this setting, the smear process will stretch the cell body cytoplasm in a pattern that mimics glial processes. Although sometimes tricky, this differentiation is critical to determining tumor lineage particularly in cases with obscuring artifacts on the sections.


Glial processes: dense strongly eosinophilic


Cytoplasm/cell body: Pale, wispy. May have "railroad track" dual densities along edges

















Metastasis Small cell carcinoma

- Neuroendocrine/small cell tumors may raggedly infiltrate from a densely cellular core.
 - Limited extent of invasion
 - Tendency to form short cords
- Cytology may be indistinguishable from small anaplastic astrocytes
- Hopefully, the smear had enough processes!









Sampling issues- Pathology

There is no way to know if the sample chosen for the smear prep is representative

- In the examples at right, using either end would give the same "correct" result (matching the FS)
- In the example at the top, the results would be different and in fact neither would match the frozen section





Sampling - Surgeon

We talked about sampling issues that are created in the lab.

Some are created by the surgeon – but that is why we got the tissue: to find out what it is for sure.


Biopsies "next to" the lesion typically require more time than lesional samples and have the added bonus of finding a way to tell the neurosurgeon that he/she missed.

Some biopsies are lesional but misleading.

Glioblastoma


Cellular tumor + Necrotizing inflammation

- Necrosis in GBM can occurs from vascular injury leading to infarction.
 - May involve tumor and/or brain
- Just like ordinary infarcts, sometimes massive PMN infiltrates occur at 1-2 days
- Not a problem if both are present, BUT...



Abscess

- Sometimes that nemesis Sampling rears its ugly head and you just get a lot of necrosis and neutrophils
- Nothing to indicate this is not an ordinary abscess
- So this conversation takes place




Abscess?GBM

Pathologist: We've got marked necrotizing inflammation – looks like an abscess

Neurosurgeon: No way! This is a tumor (you idiot).

Pathologist (In a firm calm voice): Yeah that happens sometimes with acute tumor necrosis. Just send me some tissue from a viable area.


Neurosurgeon: OK (Wow! This pathologist really knows what they are doing!)




Glioblastoma

The new biopsy does in fact have cellular tumor.

The surgeon is happy and has a newfound respect for pathologists (I can dream).






Recurrent tumor v radiation effect

A frequent biopsy question as new enhancing lesions on MRI can reflect either recurrent tumor or radiationinduced vascular injury.


Recurrent tumors are usually characterized by the presence of cellular tumor. Mitoses are strong evidence or actively growing recurrent neoplasm. This pattern is diagnostic even if there are changes of recurrence elsewhere.




Recurrent infiltrating

The other pattern of unqualified recurrence involves infiltrating diffuse growth.

This will be less cellular but the background will be relatively normal brain. In fact, were it not for the history, this pattern be indistinguishable from the infiltrating edge of a primary glioma.





A side note on types of necrosis


Brain tumor necrosis is described as either "Infarct-type" or (pseudo)palisading.


In primary/untreated tumors they have the same significance.

Infarct necrosis may be due to RT or spontaneous/intrinsic.

However, by convention, pseudopalisading necrosis is considered spontaneous/ intrinsic.

In this regard, the presence of palisading necrosisindicates recurrent tumor.






Parenchymal infarcts

Small circumscribed foci of severe edema with axonal loss or overt necrosis represent microvascular infarcts due to radiation vascular injury (the mechanism of "clinical radiation necrosis").

They are distinguished from tumor necrosis by the lack of ghost outlines of cellular tumor (parenchymal architecture may be apparent) and the surrounding background of normal or reactive brain.

A very specific indicator of treatment effect.




Individual Tumor Cells

The cells seen here are too bizarre to be radiation-induced atypia in reactive astrocytes so they are almost certainly tumor cells.

There are always residual tumor cells in treated gliomas whether you see them or not or they are in the biopsy or not.

ITC are NOT recurrent tumor. In a background of reactive changes, they are most likely residual senescent tumor cells.





Macrophages


A few individual macrophage are scattered throughout (high grade) gliomas


Large numbers are only rarely seen and clusters, parenchymal or perivascular, are so exceptional as to seriously challenge a diagnosis of recurrent tumor (or of tumor at all).

As seen here, they are all but diagnostic of treatment effect over recurrence.










Recurrent v treatment Next-to-last word

- Mild hypercellularity
- Scattered atypical cells
- Edema
- Scattered small cells
- Scattered reactive appearing astrocytes
- Vascular changes
- Would favor treatment but not straightforward ... unless the surgeon gave you the history that they were looking for recurrent metastatic carcinoma
 - RT can cause a lot of atypia
 - Lack of Hx can cause a lot of confusion




Recurrent tumor or treatment?

- Extremes cellular tumor or diffuse necrosis easy but...
- Milieu
 - Scattered atypical cells in a healthy-appearing stroma suggests tumor
 - Scattered atypical cells in a background of macrophages and necrosis suggests treatment allow a few more atypical cells here
- Macrophages are your friends
 - Clustered macrophages are almost never seen in gliomas
- Parenchymal infarcts are specific for treatment effect
- Individual tumor cells does not mean recurrence **
 - There are always tumor cells left behind; eventually the treatment will always fail and the tumor will recur unless the patient dies first from the treatment itself, a heart attack, a car accident....
- The answer is often BOTH
 - The patient did receive treatment for an incurable tumor. There will (almost) always be some treatment-related changes and the tumor will recur

 - Remember the question is really "Has the treatment failed/Is the tumor winning?"
 Definite cellular or infiltrating tumor indicates treatment failure even in a preponderant background of treatment effect
- The answer is sometimes a shrug. **
 - How many atypical cells do you need to call it "cellular"?
 - Sometimes pathology doesn't have the "right" answer pick a side and comment that the case is borderline/not definitive/or whatever term you prefer for equivocation
 - That's why tumor boards were created


Inflammatory/reactive tumor-like lesions – Multiple sclerosis


- Permanent sections usually straightforward
 - White matter
 - Circumscribed v diffusely infiltrative
 - Reactive astrocytes though
 often atypical
 - Macrophages in clusters parenchymal & perivascular
 - Myelin loss with relative axonal preservation




Multiple sclerosis

- Frozen sections often not straightforward
- Hypercellular and edematous white matter
 - Reactive astrocytes though
 often atypical
 - Atypia is clue because of low number
 - Small mononuclear cells account for most of hypercellularity








Inflammatory/Reactive v Tumor


- Changes primarily in gray matter
 - White matter less cellular – edema and a few astrocytes
- Round and slender oblong nuclei both diffusely distributed and clustered around vessels or neurons
 - Distribution suggests inflammatory
 - Lymphocytes and microglia/histiocytes




Inflammatory/Reactive v Tumor


- Cell number
 - Overall
 - By type
- Cell type
 - Astrocytes
 - Mononuclear cells
 - Microglia v astrocyte
 - MACROPHAGE
 - Clustered macrophages are almost never seen in tumor
- Cell/Lesion distribution
 - Diffuse WM Tumor
 - Circumscribed WM MS
 - Grey matter Inflammatory
 - Perivascular Inflammatory


No organisms on biopsy but autopsy confirmed Balmuthia/Acanthamoeba meningoencephalitis







7/21/2014







27












Angiomatous meningioma


- Highly vascular, poorly cellular
 Cell loss and collapse leads to approximation of hyalized blood vessels
 - More vessels than tumor cells
- Degenerative/involutional change
- (Almost) always grade I
 Hard to be aggressive and degenerative at the same time
- Closely related to microcystic meningioma
 - Similar cell loss but mucopolysaccharide-rich edema fills the space so less collapse •















IDH1 and p53


IDH1


p53


- Most common mutation in diffuse gliomas <u>– 75%</u>
 - ? Initial tumorigenic mutation
 - IDH2 mutationa less common
- Antibody is specific to mutated gene
 - Highly sensitive
 - 100% specific for diffuse glioma (Oligo/Astro)


- Widely expressed tumor suppresser gene/pathway
- p53 mutation or other defect in p53 pathway leads to accumulation (mutant or wild type) of normally transient protein
 - >50% diffuse astrocytomas
 - Rare in oligodendrogliomas
- Antibody detects both wild type and mutant















Diffuse astrocytoma v mimics Pilocytic astrocytoma

Diffuse astrocytoma









What we covered

FS challenges: Artifacts & Neurosurgeons
Smear/Crush Preparation: Friend or foe
Glioblastoma?Abscess
Recurrent?/Treatment?/???
Tumor v Inflammatory (MS): Beware of Macrophages
Meningioma/SFT/Hemangiopericytoma
IHC: IDH1!!!